Several features of COPD (dyspnea, air hunger, functional decline, and the possibility of mechanical ventilation) commonly force patients and physicians to confront end-of-life issues. Chronic ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety-provoking as it is life-affirming. The fatigue, chest tightness, congestion, and difficulty ...

She volunteered as a patient advocate and formed a nonprofit, the Hawaii COPD Coalition, which holds support groups. “It’s terribly isolating to be diagnosed with COPD, especially when you are ...

Carpets, fireworks, and hot tubs are some of the unexpected things that can hurt your lungs. Find out what you can do to prevent problems from these and other culprits.

And it doesn't give future doctors ... Apr. 23, 2024 — Patients have lower rates of mortality and hospital readmissions when treated by female physicians, with female patients benefitting more ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

The FDA approved dupilumab (Dupixent; Regeneron/Sanofi) today for treating patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 1 This approval ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved to be used as an add-on maintenance treatment by ...

The FDA decision, announced Friday, was based on a pair of late-stage trials that found Dupixent helped patients with the ... cleared for use in adults whose COPD symptoms aren’t under control ...

The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 ...